ASCO 2014

Disparities persist in early stage breast cancer treatment

By

Despite its acceptance as standard of care neary 25 years ago, barriers still exist that preclude patients from receiving breast conserving therapy (BCT), according to research presented at the ASCO 2014 Breast Cancer Symposium.

ASCO: Breathalyzer may help detect lung cancer

ASCO: Breathalyzer may help detect lung cancer

Researchers have developed a breathalyzer that can detect lung cancer and assess whether it is early or advanced, according to findings presented at the 2014 annual meeting of the American Society of Clinical Oncology.

ASCO: New treatment options available for advanced melanoma

ASCO: New treatment options available for advanced melanoma

New treatment options are available for advanced melanoma, according to three studies presented at the annual ASCO meeting.

pCR Not a surrogate for relapse-free survival in TNBC BRCA1/2 mutation carriers

pCR Not a surrogate for relapse-free survival in TNBC BRCA1/2 mutation carriers

By

In patients with triple-negative breast cancer (TNBC) who are BRCA1/2 mutation carriers, pathologic complete response (pCR) is not a surrogate for relapse-free survival, in contrast to those with non-BRCA mutations.

Does Early Integration of Palliative Care and Cancer Treatment Benefit Patients?

Does Early Integration of Palliative Care and Cancer Treatment Benefit Patients?

By

Immediately integrating cancer treatment and palliative care might improve survival at 1 year in patients with advanced cancers, suggest findings from the ENABLE III randomized controlled trial, presented at the 2014 ASCO Annual Meeting.

ASCO: Ramucirumab extends survival for NSC lung cancer

ASCO: Ramucirumab extends survival for NSC lung cancer

For patients with non-small-cell lung cancer who have relapsed after initial treatment, the addition of the anti-angiogenesis drug ramucirumab to standard docetaxel chemotherapy extends survival.

ASCO: New drug effective for metastatic prostate cancer

ASCO: New drug effective for metastatic prostate cancer

Enzalutamide, an oral androgen-receptor inhibitor, is superior to placebo for the treatment of metastatic prostate cancer before chemotherapy, according a study.

ASCO: Goserelin helps preserve ovarian function in early breast cancer

ASCO: Goserelin helps preserve ovarian function in early breast cancer

For premenopausal women with hormone receptor-negative early breast cancer treated with chemotherapy, goserelin can preserve ovarian function, according to a study presented at the annual ASCO meeting.

Early palliative support for family caregivers reduces depression

Early palliative support for family caregivers reduces depression

By

Family members caring for patients with advanced cancer benefit from early initiation of phone-based training and support.

Less frequent zoledronic acid for bone metastases safe, effective

Less frequent zoledronic acid for bone metastases safe, effective

By

In patients with breast cancer who had previously received monthly intravenous bisphosphonate therapy for bone metastases for a year or longer, maintenance zoledronic acid administered every 12 weeks was noninferior to every 4 weeks.

Reduced-dose radiation safe for certain patients with low-risk HPV-positive oropharyngeal cancer

Reduced-dose radiation safe for certain patients with low-risk HPV-positive oropharyngeal cancer

By

Reduced-dose intensity-modulated radiotherapy after complete clinical responses to induction chemotherapy for operable stage III/IVA, human papillomavirus (HPV)-positive head and neck cancer appears to be safe and might improve patients' quality of life.

Adolescent and Young Adult Cancer Survivors Report Cognitive, Sexual Late Effects

Adolescent and Young Adult Cancer Survivors Report Cognitive, Sexual Late Effects

By

Adult and young adult cancer survivors face cognitive and sexual late effects from cancer and its treatment, according to data compiled from an online cancer survivorship care planning tool presented at the 2014 ASCO Annual Meeting.

No benefits from neoadjuvant gemcitabine + carboplatin + paclitaxel in nasopharyngeal cancer

No benefits from neoadjuvant gemcitabine + carboplatin + paclitaxel in nasopharyngeal cancer

By

Patients with locally advanced nasopharyngeal cancer (NPC) do not benefit from the addition of neoadjuvant gemcitabine, carboplatin, and paclitaxel (GCP) to cisplatin chemoradiation.

Adding lapatinib to adjuvant trastuzumab not beneficial in early-stage HER2+ breast cancer

Adding lapatinib to adjuvant trastuzumab not beneficial in early-stage HER2+ breast cancer

Adding lapatinib to adjuvant trastuzumab for early-stage HER2-positive breast cancer does not improve patients' disease-free survival rates.

Exemestane + ovarian function suppression reduces recurrence risk in HR-positive early breast cancer

Exemestane + ovarian function suppression reduces recurrence risk in HR-positive early breast cancer

Adjuvant treatment with the aromatase inhibitor (AI) exemestane plus ovarian function suppression significantly reduced risk of disease recurrence in premenopausal women with hormone receptor (HR)-positive early breast cancer compared with tamoxifen plus ovarian function suppression (OFS), representing "a new treatment option for premenopausal women."

ASCO: Exemestane more effective than tamoxifen for early breast cancer

ASCO: Exemestane more effective than tamoxifen for early breast cancer

For premenopausal women with hormone receptor-positive early breast cancer, exemestane plus ovarian function suppression (OFS) is superior to tamoxifen plus OFS.

Docetaxel + ADT ups survival in metastatic prostate cancer

Docetaxel + ADT ups survival in metastatic prostate cancer

By

Upfront standard androgen deprivation therapy plus six cycles of docetaxel significantly improves overall survival compared with ADT alone in men with metastatic hormone-sensitive prostate cancer.

Baseline hypertension, ASIs affect hypertension, survival during VEGF inhibitor therapy

Baseline hypertension, ASIs affect hypertension, survival during VEGF inhibitor therapy

By

Baseline hypertension and BMI can affect worsening hypertension among patients administered vascular endothelial growth factor signaling pathway inhibitors, according to research presented at the 2014 ASCO Annual Meeting.

New way to predict response to chemotherapy in triple-negative breast cancer

New way to predict response to chemotherapy in triple-negative breast cancer

By

The presence of tumor-infiltrating lymphocytes ahead of treatment may help predict response to platinum-based chemotherapy in women with triple-negative breast cancer, according to a new study.

Safe to postpone ADT in men with asymptomatic prostate cancer and rising PSA levels

Safe to postpone ADT in men with asymptomatic prostate cancer and rising PSA levels

By

For the approximately 60,000 men in the United States with prostate cancer who are asymptomatic after radical primary treatment yet have a PSA relapse, it's safe to postpone androgen deprivation therapy, a study presented at the 2014 American Society of Clinical Oncology Annual Meeting concluded.

Depression and anxiety predict postsurgical pain in women with gynecologic cancer

By

Depression and anxiety, not just inflammation, predict pain intensity and interference with daily life among women recovering from gynecologic cancer surgery.

Ginger extract improves chemotherapy-induced nausea, vomiting

Ginger extract improves chemotherapy-induced nausea, vomiting

By

A ginger extract, 6-gingerol, improves chemotherapy-induced nausea and vomiting (CINV), according to findings from a phase 2 randomized trial presented at the 2014 Annual ASCO Meeting.

Patients' symptom concerns before anticancer treatment predict symptom burdens

Patients' symptom concerns before anticancer treatment predict symptom burdens

By

Patients who express pretreatment concern about treatment symptoms such as nausea and memory problems tend to suffer higher symptom burdens during and after anticancer treatment, suggests research.

Internal lymphedema underlies swallow dysfunction in head and neck cancer

Internal lymphedema underlies swallow dysfunction in head and neck cancer

By

Treatment-related dysphagia symptoms are likely caused by internal lymphedema among patients with head and neck cancer, according to research presented at the 2014 ASCO Annual Meeting.

Metastatic tumor sites predict OS in castration resistant prostate cancer

Metastatic tumor sites predict OS in castration resistant prostate cancer

By

The site of metastatic tumors powerfully predicts overall survival (OS) among men with metastatic castration resistant prostate cancer (mCRPC), confirms a meta-analysis presented at the 2014 American Society of Clinical Oncology Annual Meeting.

PET ΔSUV 'useful tool' to optimize neoadjuvant therapy for HER2-positive breast cancer

PET ΔSUV 'useful tool' to optimize neoadjuvant therapy for HER2-positive breast cancer

Adding bevacizumab to neoadjuvant trastuzumab plus docetaxel in tumors with a low likelihood of pathologic complete response (pCR) increased the pCR rate from 24.0% to 43.8%, a phase 2 study concluded at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting.

'Excellent' survival in biology-based pediatric neuroblastoma treatment reduction

By

Tumor biology-based therapy offers excellent outcomes among children with intermediate risk neuroblastoma, according to results from a prospective phase 3 reduction of therapy study.

Few Obese Patients with Gynecologic Cancers Counseled on Weight Loss

Few Obese Patients with Gynecologic Cancers Counseled on Weight Loss

By

Obese patients with gynecologic cancer are rarely counseled on weight loss, even though they expect to be, and report that such discussions would not offend them, according to research.

Community Cancer Centers Program Participation Increases Rural Clinical Trial Enrollment

Community Cancer Centers Program Participation Increases Rural Clinical Trial Enrollment

By

Expanding the National Cancer Institute (NCI) Community Cancer Centers Program within a rural community can increase the number of patients enrolled in clinical trials

Ridaforolimus + AKT Inhibitor Phase 1 Trial: Tolerable but Modest Efficacy for Breast Cancer

Ridaforolimus + AKT Inhibitor Phase 1 Trial: Tolerable but Modest Efficacy for Breast Cancer

By

Combination ridaforolimus + MK-2206 AKT inhibitor therapy yielded modest early clinical efficacy results for patients with low-RAS advanced breast cancer and PTEN-deficient prostate cancer.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs